RxDoctor Payments Data

Mark Sullivan, MD

Internal Medicine · Arlington, VANPI 1346669660

Payments from drug & device makers

$3,581in general payments, 2019–2025

Across 173 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$703
  • Pfizer$445
  • Lilly USA, LLC$442
  • AbbVie$349
  • Bayer$259
  • AstraZeneca$201
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,581100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,581 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$64,100
Medicare patients
185
Services billed
1,115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin31$53,548
OzempicSemaglutide32$50,920
FarxigaDapagliflozin Propanediol27$38,472
MounjaroTirzepatide23$30,710
EliquisApixaban19$22,847
SynthroidLevothyroxine Sodium12$1,593
Lidocaine14$1,292
Atorvastatin Calcium165$1,273
Rosuvastatin Calcium127$1,262
Levothyroxine Sodium99$970
Losartan Potassium107$912
Diclofenac Sodium32$798
Zolpidem Tartrate11$718
Metformin Hcl114$706
Metoprolol Succinate42$682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$110$53,54831 claims
Novo NordiskOzempic$703$50,92032 claims
AstraZenecaFarxiga$201$38,47227 claims
Lilly USA, LLCMounjaro$442$30,71023 claims
PfizerEliquis$445$22,84719 claims
AbbVieSynthroid$349$1,59312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Arlington

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →